Skip to content
  • Home
  • About
  • Contact
  • Services
  • Advertise with Us
US Pharma Marketing Logo

US Pharma Marketing

  • Industry Landscape
  • Your POV
  • Sponsored
  • Case Studies & Trends
  • Job & Career
  • Strategy & Execution
  • Digital Transformation
  • Regulatory Compliance
  • Leader Q&A

Author: Jayshree Gondane

Jayshree Gondane, BHMS student and healthcare enthusiast with a genuine interest in medical sciences, patient well-being, and the real-world workings of the healthcare system.
Why Patient Education Is Critical for Pharma Commercial Success
Posted in
  • Case Studies & Trends
  • Sponsored

Why Patient Education Is Critical for Pharma Commercial Success

Patient education is no longer an optional aspect of pharmaceutical marketing—it is central to commercial success. … Why Patient Education Is Critical for Pharma Commercial SuccessRead more

by Jayshree Gondane•February 19, 2026February 19, 2026•0
How Lack of Physician Trust Delays Drug Adoption
Posted in
  • Industry Landscape

How Lack of Physician Trust Delays Drug Adoption

Physician trust is the cornerstone of successful drug adoption. Even therapies with superior efficacy or safety … How Lack of Physician Trust Delays Drug AdoptionRead more

by Jayshree Gondane•February 19, 2026February 19, 2026•0
Why Traditional Pharma Marketing No Longer Works
Posted in
  • Industry Landscape
  • Strategy & Execution

Why Traditional Pharma Marketing No Longer Works

The pharmaceutical industry has historically relied on a predictable playbook for bringing new therapies to market. … Why Traditional Pharma Marketing No Longer WorksRead more

by Jayshree Gondane•February 19, 2026February 19, 2026•0
How Marketing and Medical Affairs Can Work Better Together
Posted in
  • Industry Landscape
  • Strategy & Execution

How Marketing and Medical Affairs Can Work Better Together

In the modern pharmaceutical landscape, few internal relationships are as strategically important as the one between … How Marketing and Medical Affairs Can Work Better TogetherRead more

by Jayshree Gondane•February 18, 2026February 18, 2026•0
Why Pharma Companies Fail at Go-To-Market Execution
Posted in
  • Industry Landscape

Why Pharma Companies Fail at Go-To-Market Execution

In the pharmaceutical industry, few moments are as consequential as the transition from regulatory approval to … Why Pharma Companies Fail at Go-To-Market ExecutionRead more

by Jayshree Gondane•February 16, 2026February 16, 2026•0
How Sales Strategy Impacts Drug Adoption After Approval
Posted in
  • Industry Landscape

How Sales Strategy Impacts Drug Adoption After Approval

A drug can clear the U.S. Food and Drug Administration, secure a label, and still stall … How Sales Strategy Impacts Drug Adoption After ApprovalRead more

by Jayshree Gondane•February 16, 2026February 16, 2026•0
Why Drugs Fail After Phase I in the U.S. Market
Posted in
  • Industry Landscape
  • Regulatory Compliance

Why Drugs Fail After Phase I in the U.S. Market

In the United States, roughly 12 percent of drugs that enter clinical testing ultimately receive approval … Why Drugs Fail After Phase I in the U.S. MarketRead more

by Jayshree Gondane•February 16, 2026February 16, 2026•0
Why Clinical Trial Data Fails to Translate Into Market Success
Posted in
  • Industry Landscape
  • Strategy & Execution

Why Clinical Trial Data Fails to Translate Into Market Success

A therapy can clear Phase III, secure FDA approval, and generate headline optimism-only to miss revenue … Why Clinical Trial Data Fails to Translate Into Market SuccessRead more

by Jayshree Gondane•February 15, 2026February 15, 2026•0
How Poor Communication Between Teams Slows Drug Development
Posted in
  • Industry Landscape
  • Strategy & Execution

How Poor Communication Between Teams Slows Drug Development

Drug development is often framed as a scientific challenge. Breakthroughs hinge on molecular discovery, biomarker validation, … How Poor Communication Between Teams Slows Drug DevelopmentRead more

by Jayshree Gondane•February 15, 2026February 15, 2026•0
Why Regulatory Delays Are Only Part of the U.S. Clinical Trial Problem
Posted in
  • Regulatory Compliance
  • Strategy & Execution

Why Regulatory Delays Are Only Part of the U.S. Clinical Trial Problem

When a development program misses projected timelines, the explanation often centers on regulatory review. FDA feedback … Why Regulatory Delays Are Only Part of the U.S. Clinical Trial ProblemRead more

by Jayshree Gondane•February 15, 2026February 15, 2026•0

Posts pagination

Previous 1 … 7 8 9 … 20 Next

Recent Posts

  • The Silent Architects: How Private Equity Is Rewriting the Rules of Pharmaceutical Commercialization
  • Location Is the New Targeting: How Geofencing Is Changing Who Gets Diagnosed and Treated
  • When a Drug Loses Its Patent, Marketing Becomes Defense, Not Growth
  • The Hidden Compliance Risk of AI in Pharmaceutical Promotion
  • The Truth About Drug Price Transparency Laws and Pharmaceutical Marketing Strategy

Recent Comments

No comments to show.
Copyright © 2026 US Pharma Marketing.
Powered by WordPress and HybridMag.
  • Industry Landscape
  • Your POV
  • Sponsored
  • Case Studies & Trends
  • Job & Career
  • Strategy & Execution
  • Digital Transformation
  • Regulatory Compliance
  • Leader Q&A